A trisubstituted benzimidazole cell division inhibitor with efficacy against mycobacterium tuberculosis

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Knudson, Susan E ^a   Awasthi, Divya ^b   Kumar, Kunal ^b   Carreau, Alexandra ^c   Goullieux, Laurent ^c   Lagrange, Sophie ^c   Vermet, Hélèn ^c   Ojima, Iwao ^b   Slayden, Richard A ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOHEXYL 5 ACYLAMINO 6 N,N DIMETHYLAMINOBENZIMIDAZOLE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; ISONIAZID; RIFAMPICIN; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BENZIMIDAZOLE; CYTOSKELETON PROTEIN; FTSZ PROTEIN, BACTERIA; RIFAMYCIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; LUNG; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMA; POLYMERIZATION; SPLEEN; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS; ANIMAL; CELL DIVISION; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROTEIN MULTIMERIZATION; TREATMENT OUTCOME;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BENZIMIDAZOLES; CELL DIVISION; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PROTEIN MULTIMERIZATION; RIFAMYCINS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84899678758     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093953     Document Type: Article

References (19)

1. Raviglione MC, Smith IM (2007) XDR tuberculosis-implications for global public health. N Engl J Med 356: 656-659.
2. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM (2007) First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 12: E070517 070511.
3. Respicio L, Nair PA, Huang Q, Anil B, Tracz S, et al. (2008) Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery. Tuberculosis 88: 420-429.
4. Kumar K, Awasthi D, Berger WT, Tonge PJ, Slayden RA, et al. (2010) Discovery of anti-TB agents that target the cell-division protein FtsZ. Future Med Chem 2: 1305-1323.
5. Slayden RA, Knudson DL, Belisle JT (2006) Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis. Microbiology 152: 1789-1797.
6. Mathew B, Ross L, Reynolds RC (2013) A novel quinoline derivative that inhibits mycobacterial FtsZ. Tuberculosis 93: 398-400.
7. Mathew B, Srivastava S, Ross LJ, Suling WJ, White EL, et al. (2011) Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors. Bioorg Med Chem 19: 7120-7128.
8. Huang Q, Kirikae F, Kirikae T, Pepe A, Amin A, et al. (2006) Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. J Med Chem 49: 463-466. (Pubitemid 43157479)
9. Huang Q, Tonge PJ, Slayden RA, Kirikae T, Ojima I (2007) FtsZ: A novel target for tuberculosis drug discovery. Curr Top Med Chem 7: 527-543. (Pubitemid 46488292)
10. Kumar K, Awasthi D, Lee SY, Zanardi I, Ruzsicska B, et al. (2011) Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. J Med Chem 54: 374-381.
11. Awasthi D, Kumar K, Knudson SE, Slayden RA, Ojima I (2013) SAR Studies on Trisubstituted Benzimidazoles as Inhibitors of Mtb FtsZ for the Development of Novel Antitubercular Agents J Med Chem 56: 9756-9770.
12. Kumar K, Awasthi D, Lee SY, Cummings JE, Knudson SE, et al. (2013) Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorg Med Chem 21: 3318-3326.
13. Camus JC, Pryor MJ, Medigue C, Cole ST (2002) Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148: 2967- 2973. (Pubitemid 35243696)
14. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM (2003) Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 47: 783-785. (Pubitemid 36158115)
15. Miyoshi-Akiyama T, Matsumura K, Iwai H, Funatogawa K, Kirikae T (2012) Complete annotated genome sequence of Mycobacterium tuberculosis Erdman. J Bacteriol 194: 2770.
16. Boyne ME, Sullivan TJ, amEnde CW, Lu H, Gruppo V, et al. (2007) Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. Antimicrob Agents Chemother 51: 3562-3567. (Pubitemid 47519344)
17. Slayden RA, Lee RE, Barry CE 3rd (2000) Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis. Mol Microbiol 38: 514-525.
18. Collins L, Franzblau SG (1997) Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 41: 1004-1009. (Pubitemid 27194176)
19. Reddy VM, Einck L, Andries K, Nacy CA (2010) In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 54: 2840-2846.